INTRODUCTION: Horses with asthma or osteoarthritis frequently receive ω-3 fatty acid supplements. Docosahexaenoic (DHA; 22:6) and eicosapentaenoic (EPA; 20:5) acids are essential ω-3 fatty acid precursors of anti-inflammatory mediators and components of structural glycerophospholipids (GPL) that act as reservoirs of these fatty acids. Analysis of the incorporation of dietary DHA + EPA into GPL pools in different body compartments has not been undertaken in horses. OBJECTIVES: We undertook a detailed study of dietary supplementation with DHA + EPA in horses and monitored incorporation into DHA- and EPA-containing glycerophosphocholines (GPC) 38:5, 38:6, 40:5, and 40:6 in plasma, synovial fluid (SF), and surfactant. METHODS: Horses (n = 20) were randomly assigned to the supplement or control group and evaluated on days 0, 30, 60, and 90. GPC in plasma, SF, and surfactant were measured by high-resolution mass spectrometry with less than 3 ppm mass error. Validation of DHA and EPA incorporation into these GPC was conducted utilizing MS2 of the [M + Cl]- adducts of GPC. RESULTS: Dietary supplementation resulted in augmented levels of GPC 38:5, 38:6, 40:5, and 40:6 in all compartments. Maximum incorporation into GPCs was delayed until 60 days. Significant increases in the levels of GPC 38:5, 40:5, and 40:6, containing docosapentaenoic acid (DPA; 22:5), also was noted. CONCLUSIONS: DHA and EPA supplementation results in augmented storage pools of ω-3 essential fatty acids in SF and surfactant GPC. This has the potential to improve the ability of anti-inflammatory mechanisms to resolve inflammatory pathways in these critical compartments involved in arthritis and asthma.
INTRODUCTION: Horses with asthma or osteoarthritis frequently receive ω-3 fatty acid supplements. Docosahexaenoic (DHA; 22:6) and eicosapentaenoic (EPA; 20:5) acids are essential ω-3 fatty acid precursors of anti-inflammatory mediators and components of structural glycerophospholipids (GPL) that act as reservoirs of these fatty acids. Analysis of the incorporation of dietary DHA + EPA into GPL pools in different body compartments has not been undertaken in horses. OBJECTIVES: We undertook a detailed study of dietary supplementation with DHA + EPA in horses and monitored incorporation into DHA- and EPA-containing glycerophosphocholines (GPC) 38:5, 38:6, 40:5, and 40:6 in plasma, synovial fluid (SF), and surfactant. METHODS: Horses (n = 20) were randomly assigned to the supplement or control group and evaluated on days 0, 30, 60, and 90. GPC in plasma, SF, and surfactant were measured by high-resolution mass spectrometry with less than 3 ppm mass error. Validation of DHA and EPA incorporation into these GPC was conducted utilizing MS2 of the [M + Cl]- adducts of GPC. RESULTS: Dietary supplementation resulted in augmented levels of GPC 38:5, 38:6, 40:5, and 40:6 in all compartments. Maximum incorporation into GPCs was delayed until 60 days. Significant increases in the levels of GPC 38:5, 40:5, and 40:6, containing docosapentaenoic acid (DPA; 22:5), also was noted. CONCLUSIONS: DHA and EPA supplementation results in augmented storage pools of ω-3 essential fatty acids in SF and surfactant GPC. This has the potential to improve the ability of anti-inflammatory mechanisms to resolve inflammatory pathways in these critical compartments involved in arthritis and asthma.
Authors: Undine Christmann; R Duncan Hite; Sharon G Witonsky; Virginia A Buechner-Maxwell; Paul L Wood Journal: Am J Vet Res Date: 2019-03 Impact factor: 1.156
Authors: Undine Christmann; R Duncan Hite; Rachel H H Tan; Craig D Thatcher; Sharon G Witonsky; Stephen R Werre; Virginia A Buechner-Maxwell Journal: Am J Vet Res Date: 2010-04 Impact factor: 1.156
Authors: Undine Christmann; Leanda C Livesey; Jennifer S Taintor; Bryan M Waldridge; John Schumacher; Bonnie L Grier; R Duncan Hite Journal: J Vet Intern Med Date: 2006 Nov-Dec Impact factor: 3.333
Authors: Stefan M Cokelaere; Saskia G M Plomp; Esther de Boef; Mike de Leeuw; Sophie Bool; Chris H A van de Lest; P René van Weeren; Nicoline M Korthagen Journal: Eur J Pharm Biopharm Date: 2018-05-03 Impact factor: 5.571
Authors: John P Caron; Jeffrey C Gandy; Jennifer L Brown; Lorraine M Sordillo Journal: Prostaglandins Other Lipid Mediat Date: 2019-03-02 Impact factor: 3.072
Authors: R E Abdulnour; H P Sham; D N Douda; R A Colas; J Dalli; Y Bai; X Ai; C N Serhan; B D Levy Journal: Mucosal Immunol Date: 2015-12-09 Impact factor: 7.313